Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Optomed

1.55 EUR+1.71 %25/9 17:29
5,666 following

OPTOMED

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Dividend
Investor views
Compare
+1.71 %
-7.96 %
-13.60 %
-34.60 %
-58.89 %
-58.78 %
-43.33 %
-86.81 %
-66.16 %

Optomed operates in the medical technology sector. The company conducts research and development of specialized eye cameras. Development takes place of both hardware and software that are resold under different brands. Operations are held on a global level, with the largest presence in the Nordic market. Customers consist of research institutes and hospitals. The company has its headquarters in Oulu.

Read more
Market cap
33.32M EUR
Turnover
30.53K EUR
P/E (adj.) (26e)
-12.25
EV/EBIT (adj.) (26e)
-8.71
P/B (26e)
1.56
EV/S (26e)
1.61
Dividend yield-% (26e)
-
Coverage
Recommendation
Accumulate
Target price
2.00 EUR
Updated
2026-08-17
Disclaimer
Juha Kinnunen
Juha Kinnunen

Analyst

Latest research

Latest analysis report

Released: 2026-08-17

Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types

Forum discussions
AEYE’s front page proudly features a $50 billion funding amount, with Optomed’s (opto) camera buzzing below it (image attached). I checked with AI (sorry) to see what the progress status of that RHTP funding is in various states, and things are moving fast over there (image). That...
9/25/2026, 11:18 AM
by Puutaheinää
36
Blood sugar levels can also be checked from retinal images. Just add a suitable AI algorithm to the Lumo camera and it’s done. Excerpt from the article. “”“”“”“”“” Conclusion: This proof-of-principle study shows AI-based HbA1c estimation, using retinal biomarkers on routine fundus...
9/24/2026, 11:47 AM
by j.sälli
21
Here is an article about Signify Health’s home visits from 2024. For 2025, the goal was to expand targeted home visits nationwide, and at that point, the targets were at least quite encouraging regarding the future. Go read it yourselves. And the article explicitly mentions visits...
9/23/2026, 7:45 PM
by carlos89
14
If playing the long game, that purchase price of €3.70 by Himberg is peanuts as things develop in the right direction. I am more than happy to grant options to management, and especially to other key personnel, not forgetting the forklift driver in the shipping department either....
yesterday
by Dr.Feelgood
12
I might even be critical, after all. The incentive needs to be a REWARD, and honestly, looking at the share price / shareholder value, it hasn’t quite hit the mark.
yesterday
by Mr. Stock
10
You’d think things are going pretty well based on the hiring: https://www.aeyehealth.com/our-careers As many as 14 positions open
yesterday
8
I’m not criticizing, but Optomed’s stock option subscription price could have been something other than yesterday’s (nearly) ATL share price. Of course, the incentive and reward are greater this way, but honestly, a “fairer” option price would have been somewhere between €2.00–€2...
yesterday
by Dr.Feelgood
8
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
6/11
2026

Interim report Q3'26

18/2
2027

Annual report '26

4/5
2027

Interim report Q1'27

Regulatory press release2026-09-25 14:30

Optomed Oyj: Optomed's Board of Directors has resolved to establish a new stock option plan

Optomed
Optomeds dotterbolag Ubetec vann Veikkauchs anbudsförfarande
Analyst Comment2026-09-07 06:55 by
Juha Kinnunen

Optomeds dotterbolag Ubetec vann Veikkauchs anbudsförfarande

Veikkaus avtalstilldelning på 0,9 MEUR stärker dotterbolaget Ubetecs position på den finländska spelmarknaden som håller på att öppnas upp.

Optomed
Regulatory press release2026-09-04 14:00

Optomed Oyj: Composition of Optomed's Shareholders' Nomination Board

Optomed

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release2026-08-18 13:10

Redeye: Optomed (Q2 Review): Sales miss offset by strong gross margin and cost control

Optomed
Optomed Q2'26: Apparatförsäljningen drar inte, men de återkommande intäkterna växer
Research2026-08-17 07:00 by
Juha Kinnunen

Optomed Q2'26: Apparatförsäljningen drar inte, men de återkommande intäkterna växer

Optomeds omsättning och vinst i Q2 var betydligt lägre än våra förväntningar, då försäljningen av utrustning fortsatte att vara svag. Positivt i rapporten var den fortsatta tillväxten i försäljningen av Aurora AEYE, minskade kostnader, ett tydligt återhämtat kassaflöde och en rekordhög bruttomarginal.

Optomed
Regulatory press release2026-08-14 12:00

Optomed Plc - Managers' transactions - Tauriainen

Optomed
Regulatory press release2026-08-14 12:00

Optomed Plc - Managers' transactions - Leppänen

Optomed
Regulatory press release2026-08-14 12:00

Optomed Plc - Managers' transactions - Wen

Optomed
Regulatory press release2026-08-14 12:00

Optomed Plc - Managers' transactions - Salonen

Optomed
Regulatory press release2026-08-14 12:00

Optomed Plc - Managers' transactions - Lee

Optomed
Regulatory press release2026-08-14 12:00

Optomed Plc - Managers' transactions - Calarco

Optomed
Regulatory press release2026-08-14 12:00

Optomed Plc - Managers' transactions - Badlani

Optomed
Regulatory press release2026-08-14 12:00

Optomed Plc - Managers' transactions - Mäkinen

Optomed
Regulatory press release2026-08-14 08:30

Optomed Oyj: Directed share issue without payment to implement Board remuneration

Optomed
Regulatory press release2026-08-14 08:30

Optomed Oyj: Optomed's financial reporting in 2027

Optomed
Regulatory press release2026-08-14 08:00

Optomed Plc: Half-year report January - June 2026

Optomed
Optomed Q2'26 förhandskommentar: Vi förväntar oss en återgång till tillväxt och övervakar kassaflödet
Analyst Comment2026-08-11 07:02 by
Juha Kinnunen

Optomed Q2'26 förhandskommentar: Vi förväntar oss en återgång till tillväxt och övervakar kassaflödet

Vi estimerar att omsättningen har ökat i takt med att försäljningen av utrustning återhämtat sig från en svag inledning på året.

Optomed
Press release2026-06-23 09:43

Redeye: Optomed: Solid device order

Optomed
Optomed fick en order på 1,8 MEUR för utrustning från USA
Analyst Comment2026-06-22 06:58 by
Atte Riikola

Optomed fick en order på 1,8 MEUR för utrustning från USA

Ordern överstiger hela årets intäkter från utrustning och stärker kassan.

Optomed
Regulatory press release2026-06-18 16:30

Inside Information: Optomed receives a large order in the US

Optomed